SARS-CoV-2 Genome Sequence: FIN-UH25M-C1P1/2020 (MZ962407.1)

March 23, 2026 Dr. Michael Lee – Health Editor Health

Researchers are utilizing machine learning to identify potential therapeutic targets for COVID-19, focusing on the human protein C1-inhibitor (C1-INH), encoded by the SERPING1 gene. This function, detailed in a recent publication, stems from the global disruption caused by the rapid transmission of SARS-CoV-2.

The study, which analyzed transcriptomic data from blood, nasal, and buccal tissues (accession number GSE183071), identified SERPING1 as a consistently appearing candidate marker across all datasets. Researchers then conducted an immuno-informatics study on the C1-INH protein, identified by protein identifier 5DU3, to assess its antigenicity, major histocompatibility (MHC) Class I and II binding epitopes, allergenicity, toxicity, and immunogenicity.

The investigation screened peptides based on these metrics to determine their suitability for vaccine design. Further analysis revealed a strong association between the SERPING1 gene and the compound Rhucin. A model-free biomarker selection technique, HSIC-Lasso, was employed to pinpoint genes exhibiting a nonlinear relationship with the target class, ultimately informing the training of supervised machine learning models using a leave-one-out cross-validation method. Explainable artificial intelligence techniques were then used to interpret the models.

Alongside these computational efforts, diagnostic tools for SARS-CoV-2 detection continue to evolve. The LumiraDx SARS-CoV-2 Ag Test, a rapid microfluidic immunofluorescence assay, is designed for employ with the LumiraDx Platform and detects nucleocapsid protein antigens in direct anterior nasal and nasopharyngeal swab specimens collected from individuals suspected of having COVID-19. Reference and research reagents, including standards, are also available through the National Institute for Biological Standards and Control (NIBSC) to support diagnostics, vaccine development, and broader SARS-CoV-2 research.

The Quick SARS-CoV-2 Multiplex Kit, offered by Zymo Research, provides a highly sensitive and specific molecular test with increased throughput. The study of molecular interactions, such as those involving C1-INH, continues in parallel with the development and refinement of diagnostic capabilities.